Market Cap | 71.28M | P/E | - | EPS this Y | 58.20% | Ern Qtrly Grth | - |
Income | -119.58M | Forward P/E | -0.72 | EPS next Y | 0.10% | 50D Avg Chg | -5.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -47.00% |
Dividend | N/A | Price/Book | 0.23 | EPS next 5Y | - | 52W High Chg | -93.00% |
Recommedations | 2.00 | Quick Ratio | 14.46 | Shares Outstanding | 6.50M | 52W Low Chg | 16.00% |
Insider Own | 6.84% | ROA | -12.45% | Shares Float | 1.61M | Beta | 1.22 |
Inst Own | 76.01% | ROE | -48.65% | Shares Shorted/Prior | 259.47K/12.02K | Price | 0.55 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 610,745 | Target Price | 103.67 |
Oper. Margin | - | Earnings Date | Nov 11 | Volume | 236,569 | Change | -0.36% |
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
HC Wainwright & Co. | Buy | Sep 17, 24 |
HC Wainwright & Co. | Buy | Sep 16, 24 |
Baird | Outperform | Sep 16, 24 |
Baird | Outperform | Sep 13, 24 |
HC Wainwright & Co. | Buy | Sep 12, 24 |
HC Wainwright & Co. | Buy | Aug 23, 24 |
HC Wainwright & Co. | Buy | Aug 5, 24 |
HC Wainwright & Co. | Buy | May 13, 24 |
Baird | Outperform | May 13, 24 |